Navigation Links
Large Vein Occlusive Disease: Diagnosis and Treatment Options to be Presented at the 40th Annual VEITHsymposium in New York
Date:11/20/2013

NEW YORK, Nov. 20, 2013 /PRNewswire-iReach/ -- Large vein occlusive disease is on the rise, especially in diabetic patients.  Management of deep vein thrombosis (DVT) of the upper extremity due to thoracic outlet syndrome compressing the subclavian vein and of the lower extremity due to iliac vein stenosis remains controversial.  Media is invited to attend any and all presentations relative to large vein occlusive disease presented at the 40th Annual VEITHsymposium in New York. The session will commence on Thursday, November 21st, 1:00 P.M. to 5:00 P.M. located in Americas Hall I, 3rd Floor of the New York Hilton-Midtown (NY, NY). Kenneth Ouriel, MD, MBA, FACS, FACC will moderate the session.

    Dr. Ouriel said, "This session will be particularly interesting to the media.  We will discuss state-of-the-art diagnostic and treatment modalities for large vein occlusion in the upper and lower extremities.  Therapy for axillo/subclavian and lower extremity venous stenotic and occlusive disease continues to evolve, with accumulating data on pharmacologic, mechanical, and open surgical modalities. There is much to be learned."  Media will have an opporunity to interview presenters in the VEITHsymposium press office. 

     The recent advent of stents engineered specifically for the venous anatomy and physiology provides a timely setting to discuss the indications and early outcome of endovascular therapy for venous occlusion.  Lastly, clinicians who are highly skilled in these demanding procedures will present the indications and operative techniques for major open surgical reconstruction of the vena cava and other large veins. 

     Ouriel concluded, "In short, accumulating data on large vessel venous occlusion affords opportunities for the patient and the vascular practitioner alike.  Newly gained knowledge of the disease and the results of treatment can be applied to a larger proportion of the underserved population with venous disease; at the same time expanding the armamentarium of effective interventions available to the practicing clinician."  

     Experts will address the unmet needs and opportunities for the future, other commonly encountered venous occlusive problems and their treatment, treatment of lower extremityDVT, balloons, stents, thrombolysis, ultrasound thrombolysis, mechanical thrombectomy, and inferior vena caval issues (including endovascular and open surgical management). 

     About VEITHsymposium: Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 750 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend the VEITHsymposium, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780 or email.

Media Contact: Pauline Mayer, PTM Healthcare Marketing, Inc., 631-979-3780, ptm@ptmhcm.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE VEITHsymposium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
2. Does Your Business Have the Tools to Compete in the Worlds Largest Diagnostics Markets?
3. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
4. DNA Diagnostics Center (DDC), One of the Worlds Largest DNA Testing Companies, Increases the Identification Power of its DNA Tests by More Than 500%
5. B. Braun Receives FDA Approval For New Large-Volume Irrigation Containers
6. B. Braun Receives FDA Approval For New Large-Volume Intravenous Containers
7. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
8. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
9. Large-Scale Global Registry to Examine Treatment Patterns and Disease Burden Among Patients with Venous Thromboembolism (VTE)
10. SERVE-HF; the Worlds Largest Study of Sleep-Disordered Breathing in Heart Failure Completes Recruitment
11. Large-Scale Kaiser Permanente Program Linked to Improved Blood Pressure Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... In honor of Military Spouse Appreciation ... and the National Military Family Association, a nonprofit that works to strengthen and ... scholarship recipient of 2016. , “Being awarded this scholarship by Career Step, ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for ... an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... injectables (LAIs), today announced a development collaboration with the Australian critical medicine ... mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu ... red, green, and brown seaweeds. The pair observed that when photosynthetically active radiation ...
Breaking Medicine News(10 mins):